As efforts to control malaria are stalling, and the disease is particularly severe in children under the age of two, it is imperative for countries in sub-Saharan Africa, with areas of moderate-to-high transmissions, to implement Perennial Malaria Chemoprevention (PMC) delivered through the Expanded Program on Immunization (EPI), which is the only feasible, sustainable and cost-effective strategy to reach this high-risk group. PMC is a full therapeutic course of antimalarial medicine (with sulfadoxine-pyrimethamine, SP) delivered to infants in the context of routine immunisation services during the first two year of life.
PMC has been shown to be safe, efficacious in reducing clinical malaria, anaemia and hospital admissions, and to be highly cost-effective; for all these reasons, the World Health Organization (WHO) recommended in 2010 Intermittent Preventive Treatment for Infants (IPTi) for malaria prevention. Only one African country - Sierra Leone -put IPTi into policy and practice. Concerned with this slow adoption, WHO in 2019 recommended adaptations be urgently tested through pilots assessing impact, operational feasibility and cost effectiveness. In 2022, WHO expanded that recommendation to cover children through the age of two because of studies documenting the value in children aged 12 to 24 months. The name for this preventive treatment has consequently changed to Perennial Malaria Chemoprevention (PMC) as the updated recommendation is no longer just for infants.
MULTIPLY is the pilot implementation of PMC in selected districts in Mozambique, Sierra Leone and Togo to maximise the delivery and uptake of PMC, to achieve the full potential of this intervention. Working with the ministries of health in Mozambique, Sierra Leone and Togo, MULTIPLY will give up to 6 doses of PMC in the first two years of life. PMC will be given at health facilities and EPI mobile outreach clinics using a paediatric dispersible formulation of SP, alongside routine vaccinations and vitamin A supplementation.

开始日期2022-02-14

申办/合作机构

Barcelona Institute for Global Health

[+4]

NCT04336189

/ Completed临床3期IIT

Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda

This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) + dihydroartemisin-piperaquine (DP) will significantly reduce the risk of adverse birth outcomes compared to IPTp with SP alone or DP alone. This double-blinded randomized controlled phase III trial of 2757 HIV uninfected pregnant women enrolled at 12-20 weeks gestation will be randomized in equal proportions to one of three IPTp treatment arms: 1) SP given every 4 weeks, or 2) DP given every 4 weeks, or 3) SP+DP given every 4 weeks. SP or DP placebos will be used to ensure adequate blinding is achieved in the study and follow-up will end 28 days after giving birth.

开始日期2020-12-28

申办/合作机构

The University of California, San Francisco

[+1]

NCT03749369

/ Unknown status早期临床1期IIT

Effect of Salvadora Persica on Clinical, Radiographic and Microbiological Parameters of Chronic Periodontitis: A Triple-Blind Randomized Controlled Clinical Trial

A randomized controlled triple blinded study to evaluate the effectiveness of Salvadora Persic (SP) as an adjunct to Scaling and Root Planing (SRP) in chronic periodontitis by comparing the basic parameters of periodontitis, radiographs and bacterial levels with a controlled group (SRP only).

开始日期2019-04-01

申办/合作机构

King Saud University

[+1]

100 项与山柑藤根提取物相关的临床结果

登录后查看更多信息

100 项与山柑藤根提取物相关的转化医学

登录后查看更多信息

100 项与山柑藤根提取物相关的专利（医药）

登录后查看更多信息

项与山柑藤根提取物相关的文献（医药）

2025-04-01·Journal of Ethnopharmacology

Pharmacological evaluation of Salvadora persica in modulating Lipopolysaccharide and Cigarette smoke-induced acute lung injury; an in-vitro, in-vivo, and in-silico approach

Article

作者: Fatima, Mobeen ; Hussain, Musaddique ; Khan, Kashif Ur Rehman ; Al-Joufi, Fakhria A

ETHNOPHARMACOLOGICAL RELEVANCEARDS (Acute Respiratory Distress Syndrome) and ALI (Acute Lung Injury) are severe pulmonary alterations manifested by amplified inflammatory and oxidative responses contributing to high mortality rates. ALI triggered by various provoking factors, including cigarette smoke (CS), or pathogens (Lipopolysaccharide or SARS-CoV-2), cause severe life-threatening morbidities. Salvadora persica has been used across various countries for cough and asthma, however; there is a paucity of data on its use in ALI.AIM OF THE STUDYThis research explores signaling pathways and the potential of S-persica in treating ALI, emphasizing the feasibility of its compounds being advanced into therapeutic agents via pre-clinical trials and computational approaches.MATERIALS AND METHODSIn-vitro, GC-MS, phytochemicals, antioxidants (Phosphomolybdenum, DPPH, ABTS⁺, and FRAP), and enzyme inhibition (AChE & BChE) assays were performed. 60 rats were divided into 12 groups (n = 5 each), and assigned to SP-mx (100, 200, and 300 mg/kg), Dexa (1 mg/kg), Control (NS), LPS-challenged and CS-exposed groups, to establish in-vivo models. After 24 h (LPS-challenged) and day 10th (CS-exposure), oxygen saturation, inflammatory cells, lung weight, histopathology, MDA, TOS, TAC, and mRNA expression of IL-1β, TNF-α, IL-6, NF-κβ, COX-2, IL-4 and IL-10 were evaluated. Further, in-silico studies were conducted via Docking, Swiss ADME, Molinspiration, and ProTox-III.RESULTSIn both models, SP-mx reduced edema, inflammatory cells infiltration, histopathological alterations, oxidative stress, expression of pro-inflammatory cytokines, COX-2 and NF-κB, while elevating TAC and anti-inflammatory cytokines. Its high phenolic contents along with antioxidant and anticholinesterase activities, endorsed SP-mx remarkable ability to combat oxidative stress. In-silico studies confirmed its interactions with AChE, BChE, COX-2, TNF-α, IL-1β, and NF-κB, as well as its favorable ADMET, and drug-likeness properties.CONCLUSIONThese findings highlight that SP-mx is a potential therapeutic candidate for treating ALI by possibly modulating COX-2/NF-κB signaling pathways, warranting further research for clinical translation.

2023-06-20·Oral health & preventive dentistry

Efficacy of 0.12% Chlorhexidine and Salvadora persica-based Mouthwash in Reducing Oral Candida Carriage and Periodontal Inflammation in Cigarette Smokers and Non-smokers after Non-surgical Periodontal Therapy.

Article

作者: Al-Zawawi, Abeer S ; Divakar, Darshan Devang ; Shaheen, Marwa Y ; Basudan, Amani M ; Aldulaijan, Hajer A

PURPOSEThe present study assessed the efficacy of 0.12% chlorhexidine (CHX) and Salvadora persica-based mouthwashes (SPM) in reducing oral Candida carriage (OCC) and periodontal inflammation in cigarette smokers and non-smokers after non-surgical periodontal treatment (NSPT).MATERIALS AND METHODSSelf-reported cigarette smokers and non-smokers with periodontal inflammation as well as non-smokers with a healthy periodontal status were included. NSPT was performed in all participants. Based on the type of mouthwash, participants were randomly divided into three groups as follows: group 1: CHX; group 2: SPM; and group 3: distilled water (ddH2O) with mint flavour (control group). Clinical attachment loss (CAL), plaque index (PI), gingival index (GI), probing depth (PD), and marginal bone loss (MBL) were measured. Clinical periodontal parameters were re-assessed at a 6-week follow-up. Oral yeast samples were collected and identified using a concentrated oral-rinse culture technique and PCR, respectively. Clinical and laboratory-based investigations were done at baseline and after six weeks. Statistical significance was set at p < 0.05.RESULTSAt baseline, PI, MBL, PD and CAL were comparable in all participants. None of the patients had periodontitis at baseline. Post-operatively, CHX and SPM were more effective in reducing PI (p < 0.01), GI (p < 0.01) and PD (p < 0.01) in non-smokers than in the control group. The OCC was statistically significantly higher among smokers compared with non-smokers at baseline. At the 6-month follow-up, CHX was more effective than SPM in reducing OCC in non-smokers (p < 0.01). At the 6-week follow-up, there was no difference in OCC among cigarette smokers regardless of the type of mouthwash prescribed postoperatively.CONCLUSIONIn cigarette smokers and non-smokers, CHX and SPM are effective in reducing periodontal soft-tissue inflammation after NSPT. Post-operative use of CHX is more effective than SPM in reducing OCC.

2022-10-01·European review for medical and pharmacological sciences

Effectiveness of 0.12% chlorhexidine and a Salvadora persica-based mouthwash in reducing periodontal inflammation and whole salivary IL-1β levels after non-surgical periodontal therapy in young light cigarette-smokers.

Article

作者: Divakar, D D ; Shaheen, M Y ; Aldulaijan, H A ; Basudan, A M ; Al-Zawawi, A S

OBJECTIVEThe aim was to assess the effectiveness of 0.12% chlorhexidine (CHX) and a Salvadora persica (SP)-based mouthwash in reducing periodontal inflammation and whole salivary interleukin (IL)-1β levels after non-surgical periodontal therapy in young light cigarette-smokers.PATIENTS AND METHODSSelf-reported current cigarette-smokers and never-smokers with periodontal inflammation were included. All patients underwent non-surgical periodontal therapy. Patients were divided into 2 subgroups. In the test- and control-group, patients were advised to rinse with a Salvadora persica-based mouthwash and a non-alcoholic 0.12% CHX twice daily for 2-weeks, respectively. Full-mouth plaque index (PI), gingival index (GI), probing depth (PD) and clinical attachment loss (AL) and whole salivary IL-1β were measured at baseline and at 3-months' follow-up. Significance was set at p<0.01.RESULTS34 cigarette-smokers and 34 never-smokers were included. At 3-months of follow-up, PI, PD, and clinical AL were comparable with their respective baseline values among cigarette-smokers. In never-smokers, there was a significant reduction in scores of PI (p<0.01), GI (p<0.01) and PD (p<0.01) at 3-months of follow-up compared with baseline. At 3-months of follow-up, there was no significant difference in PI, GI, PD, and clinical AL among never-smokers in the test- and control-groups. Among never-smokers, there was a significant reduction in whole salivary IL-1β levels at 3-months' follow-up (p<0.01).CONCLUSIONSUsage of 0.12% CHX or a S. persica-based mouthwash following NSPT is ineffective in controlling periodontal inflammation and reducing whole salivary IL-1β in young light cigarette-smokers compared with never-smokers.

100 项与山柑藤根提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性牙周炎	临床1期	-	King Saud University	2019-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GU2016	N/A	-	18	Whole prostate sPPI	糧淵鏇構窪願觸膚鬱鬱(遞壓選蓋齋築餘遞糧構) = 製鹽獵醖憲鬱憲淵膚夢壓艱製鬱膚網積廠壓膚 (蓋憲簾壓構齋簾願觸鏇 ) 更多	-	2016-01-10
				Focal sPPI	願獵憲鬱製糧窪簾衊鏇(築積範淵膚積觸餘觸鏇) = 範構繭鏇齋積壓顧顧遞憲構繭遞鏇獵願衊鑰選 (鬱遞餘製糧顧蓋齋衊簾, Gy^2)